ClinicalTrials.gg
TerminatedNCT05942820Updated Mar 20, 2024

The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers

A Phase 1 interventional study of BWC0977 and Placebo in Infectious Diseases and Bacterial Infections, sponsored by Bugworks Research Inc.. Terminated at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Bugworks Research Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
CMC challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Communicable Diseases with a site in Australia — 5 open to participants now, 5 under way, none of them phase 3. Communicable Diseases · Australia.

Started
2023
the only one that year
Phase 1
4 of 11
1 open now
Registered
7th of 11
by date
Lead sponsor
3 of 11
Bugworks Research Inc.

Among the 11 studies in Communicable Diseases with a site in Australia, this one is the only one that started in 2023, is one of 4 in phase 1, and was the 7th registered.

Communicable Diseases

627 studies on the registry are indexed under Communicable Diseases; 128 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

5 of the 11 studies in Communicable Diseases with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Communicable Diseases with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple intravenous doses of BWC0977 when administered to healthy adult volunteers.

Read the detailed description

This Phase 1 study is designed to assess the safety, tolerabilty and pharmacokinetics of single and multiple intravenous doses of BWC0977 when administered to healthy adult volunteers. This is a randomized double-blind, placebo-controlled, ascending dose, multi-cohort trial. A total of 56 healthy volunteers are expected to be enrolled into 7 Cohorts. The study will be conducted in two phases: A multiple ascending dose (MAD) phase , followed by A single ascending dose (SAD) phase. In SAD, participants in Cohorts 1 - 2 will receive one dose of BWC0977 or placebo. In MAD, participants in Cohorts 6 - 8 will receive multiple doses of BWC0977 or placebo for 10 consecutive days at a dose deemed safe and tolerable as determined in the preceding SAD Cohorts. In both parts sequential cohorts will be exposed to increasing doses of BWC0977.

03

Conditions studied

  • Infectious Diseases
  • Bacterial Infections

Keywords

  • Safety
  • Tolerability
  • Pharmacokinetics
  • BWC0977
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each subject must meet all the following criteria to be eligible for study participation:

  1. Healthy male or female 18 to 55 years of age, inclusive, at time of consent.
  2. (BMI) ≥ 19.0 and ≤ 30.0 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).
  3. Medically healthy without abnormalities at the screening visit, Day -1 or Day 1, including:

    1. No findings in Physical examination or vital signs (including temperature, HR, respiratory rate, and blood pressure) that the Investigator determines would interfere with interpretation of study results.
    2. (ECGs) without clinically significant abnormalities, including a interval duration ≤450 msec (for males), and ≤470 msec (for females) obtained as an average from the triplicate screening ECGs after at least 5 minutes in a supine quiet-rest position.
    3. Clinically significant abnormalities in the screening clinical laboratory tests, as determined by the Investigator. Repeat testing could be performed at the Investigator's discretion.
  4. Willing and able to provide written .
  5. Agrees to be available for all study visits and cooperate fully with the requirements of the study protocol, including the schedule of events.
  6. Willing to refrain from strenuous physical activity that could cause muscle aches or injury, including contact sports, at any time from 4 days prior to admission in the clinical research unit (CRU) until completion of the study (follow-up [FU] visit).
  7. Willing to refrain from prescription medications from Screening visit until follow-up; and over-the-counter (OTC) medications, vitamin preparations and other food supplements, from Day -1 up to follow-up.
  8. Have suitable venous access for drug administration and blood sampling.
  9. If female of , must agree to and comply with:

    1. Using 1 barrier method (e.g., female condom or male partner using a condom) plus 1 other highly effective method of (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, vasectomized partner), or double-barrier method (use of a condom by the male partner with use of a diaphragm by the female partner), from signing the consent form until 30 days after last study drug administration, or
    2. Sexual abstinence, for the duration of the study (from signing of consent to FU visit) and for 30 days after last study drug administration, plus
    3. Females of child-bearing potential must also agree not to donate ova or oocytes (ie, human eggs) during the study, and for one menstrual cycle after completion of the study.
    4. To be considered of non-childbearing potential, a female must have either a tubal ligation, hysterectomy, bilateral salpingo-oophorectomy (at least 6 weeks prior to screening), or menopause (last menstruation >12 months and FSH in menopausal range); provision of written documentation is not required for female sterilization and oral confirmation is adequate.
    5. Female participants in same sex relationships do not need to utilize contraception.
  10. Male volunteers, if sexually active with a female partner, must agree to and comply with using 1 barrier method of birth control (e.g., male condom) plus 1 other highly effective method of birth control in their partner (e.g., oral contraceptive; implant, injectable, indwelling intrauterine device), or double-barrier method (use of a condom by the male partner with use of a diaphragm by the female partner, or sexual abstinence, and must not donate sperm, for the duration of the study (from signing of consent) and for 90 days after last study drug administration.

To be considered surgically sterile, male participants must have had a vasectomy at least 3 months prior to screening with appropriate documentation of the absence of sperm in the ejaculate.

Male participants in same sex relationships do not need to utilize contraception.

Exclusion criteria

Exclusion Criteria:

Volunteers who meet any of the following criteria will be excluded from the study:

  1. Women who are pregnant and/or lactating.
  2. History or presence of significant cardiovascular (including , hypokalemia, or other proarrhythmic conditions), pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine (including glucose intolerance, diabetes mellitus), immunologic (including asthma or seasonal allergies [that require intermittent use of or other medication]), musculoskeletal (including tendinopathy), dermatologic, or neurological disease (including seizure disorders, psychiatric disorders), including any acute illness or surgery within the past 3 months, as determined by the Investigator to be clinically relevant.
  3. A serum creatinine value on Day -1 (check-in) that increased by more than 0.2 mg/Dl (or 15.25 μmol/L) from the Screening value. Note: the serum creatinine test may be repeated prior to confirming exclusion.
  4. History of photosensitivity to quinolones.
  5. History of known or suspected Clostridium difficile infection.
  6. Any condition that necessitated hospitalization within the 3 months prior to Day -1 or is likely to require so during the study.
  7. Positive test for HbsAg, anti- antibodies, or antibodies to -1, HIV-2 at screening.
  8. Exposure to any prescription medications (small molecules, biologics, and vaccines, including influenza and/or COVID-19 vaccines) or, systemically administered OTC drugs, dietary supplements, or herbal remedies, within 14 days or 5 half-lives (if known), whichever is longer, prior to Day 1 (first dose). Participants should not receive any vaccinations (including influenza and/or COVID-19 vaccines) until after study completion. Discussion between the PI and the Sponsor Medical Monitor is encouraged regarding prior use of any medications during the pre-dose period.

    Note: An exception is made for hormonal and a limited amount of paracetamol (a maximum of 4 doses per day of 500-mg paracetamol, and no more than 3 g per week) for the treatment of headache or any other pain.

  9. Documented reaction or anaphylaxis to any medication.
  10. Smoker (including tobacco, e-cigarettes, or marijuana) or nicotine user within 1 month prior to dosing and have a negative test for cotinine at check in on Day -1 (may be repeated once, at the discretion of the Investigator, in the instance of a positive result).
  11. Positive urine drug/alcohol testing at screening or check-in (Day -1), or history of substance abuse or alcohol abuse (defined as greater than 2 standard drinks on average each and every day, where one standard drink is defined as containing 10 g of alcohol and is equivalent to 1 can or stubby of mid-strength beer, 30 ml nip spirits, or 100 ml wine) within the previous 5 years (may be repeated once per timepoint, at the discretion of the Investigator, in the instance of a positive result).
  12. Donation of blood or plasma within 30 days prior to randomization, or loss of whole blood of more than 500mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of study enrollment.
  13. Previous participation in this study or previous participation in another study within 5 half-lives (if known) of the agent, or 30 days, whichever is longer, of Day 1.

    Note: prior participation at any time in non-invasive methodology trials in which no drugs were given is acceptable.

  14. Consumption of red wine, Seville oranges, grapefruit, or grapefruit juice, pummelos, other citrus fruits, grapefruit hybrids or fruit juices containing such products from 7 days prior to the first dose of study medication.
  15. Employee or family member of an employee of the Sponsor, clinical research unit, or clinical research organization at which the study will be conducted.
  16. Unable to cooperate fully with the requirements of the study protocol, including the schedule of events, or likely to be non-compliant with any study requirements.
  17. Any disease or condition (medical or surgical) that, by the determination of the Investigator, precludes the subject's participation in the study or would place the subject at risk as a result of participation in the study.

Note: Volunteers should refrain from consumption of any foods containing poppy seeds within 48 hours (2 days) prior to screening and prior to Day -1 to avoid false positive drug screen results

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    BWC0977

    MAD Cohorts: Subjects will receive multiple doses of 240mg BID 7 days, 750mg BID 10 days,1250mg BID 10 days and 1000mg TID 10 days BWC0977 via IV infusion over 2 hours in the first 4 cohorts. The dose for the A5 cohort will be determined based on safety and tolerability data from the previous cohorts Up to five dose groups will be studied. SAD Cohorts: Subjects will receive single doses of BWC0977 via IV infusion over 2 hours. The planned dose to be studied are 1500mg. Upto 2 cohorts will be studied

    Drug: BWC0977

  • Placebo comparator
    Placebo

    Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hours. MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hours for 7 or 10 consecutive days.

    Drug: Placebo

Interventions

  • SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.

  • DrugPlacebo

    SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo. Other Names: • Compounded solution minus BWC0977

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs and serious adverse events (SAEs) overall and by intensity (Safety and tolerability).

    This outcome combines the measure of the number of participants experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatment

    Time frame: SAD: Up to 7 days; MAD: Up to 15 days

Secondary outcomes

  1. AUC[0-t] of BWC0977 following single dose administration

    Area under the plasma concentration curve from time zero to last time of quantifiable concentration (AUC\[0-t\]) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  2. AUC[0-inf]) of BWC0977 following single dose administration

    AUC from time zero to infinity (AUC\[0-inf\]) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  3. AUC[0-8], AUC[0-12], AUC[0-24]) of BWC0977 following single dose administration

    AUC from time zero to 8, 12, and 24 hours (AUC\[0-8\], AUC\[0-12\], AUC\[0-24\]) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  4. Cmax of BWC0977 following single dose administration

    Maximum observed plasma concentration (Cmax) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  5. Cmax of BWC0977 following repeat dose administration

    Maximum observed plasma concentration (Cmax) of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start]

  6. Terminal half-life (T1/2)

    Terminal half-life (T1/2) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  7. Systemic clearance (CL) following single dose administration

    Systemic clearance (CL) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  8. Systemic clearance (CL) following repeat dose administration

    Systemic clearance (CL) of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start]

  9. Volume of distribution at steady state (Vdss) following single dose administration

    Volume of distribution at steady state (Vdss) of BWC0977 following single dose

    Time frame: Day 1 pre-dose, 5, 10,15, 20, 30, 45, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 hours post infusion start

  10. Pre-dose (trough) concentration (Cτ) at the end of the dosing interval

    Pre-dose (trough) concentration (Cτ) at the end of the dosing interval of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start]

  11. Observed accumulation ratio following repeat dose administration

    Observed accumulation ratio (Ro) of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start

  12. Volume of distribution at steady state following repeat dose administration

    Volume of distribution at steady state (Vdss) of BWC0977 following repeat dose

    Time frame: Day 1 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, and 8 hours post infusion start Days 5, 6, 7, 8, and 9: pre-dose Day 10 pre-dose, 30, 60, 75, and 90 minutes and 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 hours post infusion start

  13. Amount excreted in urine (Ae) following repeat dose administration

    Amount excreted in urine (Ae) of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 0-8 hours post infusion start Day 10: 0-8 hours post infusion start

  14. Amount excreted in urine (Ae) following single dose administration

    Amount excreted in urine (Ae) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 0-2, 2-4, 4-8, 8-12, and 12-24 hours post infusion start

  15. Fraction of the dose excreted in urine (fe) following single dose administration

    Fraction of the dose excreted in urine (fe) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 0-2, 2-4, 4-8, 8-12, and 12-24 hours post infusion start

  16. Fraction of the dose excreted in urine (fe) following repeat dose administration

    Fraction of the dose excreted in urine (fe) of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 0-8 hours post infusion start Day 10: 0-8 hours post infusion start

  17. Renal Clearance (CLr) following single dose administration

    Renal Clearance (CLr) of BWC0977 following single dose administration

    Time frame: Day 1 pre-dose, 0-2, 2-4, 4-8, 8-12, and 12-24 hours post infusion start

  18. Renal Clearance (CLr) following repeat dose administration

    Renal Clearance (CLr) of BWC0977 following repeat dose administration

    Time frame: Day 1 pre-dose, 0-8 hours post infusion start Day 10: 0-8 hours post infusion start

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Jan 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 12, 2023
StartActual
Aug 30, 2023
Primary completionActual
Jan 30, 2024
CompletionActual
Feb 15, 2024
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942820
Lead sponsor
Bugworks Research Inc.
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Aug 30, 2023
Primary completion
Jan 30, 2024
Completion
Feb 15, 2024
Last update
Mar 20, 2024

Study contacts

Nicholas Farinola, BSc,BMBS
principal investigator · CMAX Clinical Research ,Adelaide, SA, Australia, 5000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BWC0977

Start the discussion